MONOCLONAL-ANTIBODY PAL-M1 RECOGNIZES THE TRANSFERRIN RECEPTOR AND IS A PROGRESSION MARKER IN MELANOCYTIC LESIONS

被引：28

作者：

VANMUIJEN, GNP ^{[1
]}

RUITER, DJ ^{[1
]}

HOEFAKKER, S ^{[1
]}

JOHNSON, JP ^{[1
]}

机构：

[1] UNIV MUNICH,DEPT IMMUNOL,W-8000 MUNICH 2,GERMANY

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1990年 / 95卷 / 01期

关键词：

D O I：

10.1111/1523-1747.ep12873947

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Monoclonal antibody PAL-M1, which was selected to discriminate between nevocellular nevi and cutaneous melanomas, has not been characterized until now. Here we show that PAL-M1 is directed against the transferrin receptor (CD71). The molecules precipitated by PAL-M1 and by anti-transferrin receptor antibodies OKT9 and 5E9 from various human tumor cell lines (melanoma, hepatoma, and lymphoma) show identical characteristics on SDS-PAGE. PAL-M1 also specifically recognized mouse L cells expressing the human transferrin receptor gene. Competition experiments demonstrated that PAL-M1 and OKT9 recognize the same or a spatially close determinant. Immunohistochemical staining of a large series of melanocytic lesions indicates that the transferrin receptor can be considered as a progression antigen in this type of lesion. © 1990.

引用

页码：65 / 69

页数：5

共 47 条

[1] CONTROLLED SYNTHESIS OF HBSAG IN A DIFFERENTIATED HUMAN-LIVER CARCINOMA-DERIVED CELL-LINE [J].